MX2023014901A - Nanoparticulas que contienen acido nucleico. - Google Patents
Nanoparticulas que contienen acido nucleico.Info
- Publication number
- MX2023014901A MX2023014901A MX2023014901A MX2023014901A MX2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A
- Authority
- MX
- Mexico
- Prior art keywords
- nanoparticles
- nucleic acid
- acid containing
- containing nanoparticles
- cationic lipid
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 5
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 102000007592 Apolipoproteins Human genes 0.000 abstract 2
- 108010071619 Apolipoproteins Proteins 0.000 abstract 2
- -1 cationic lipid Chemical class 0.000 abstract 2
- 229930182558 Sterol Natural products 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21180786 | 2021-06-22 | ||
| PCT/EP2022/067073 WO2022268913A1 (en) | 2021-06-22 | 2022-06-22 | Nucleic acid containing nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014901A true MX2023014901A (es) | 2024-04-29 |
Family
ID=76553579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014901A MX2023014901A (es) | 2021-06-22 | 2022-06-22 | Nanoparticulas que contienen acido nucleico. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240216291A1 (enExample) |
| EP (1) | EP4358936A1 (enExample) |
| JP (1) | JP2024526202A (enExample) |
| KR (1) | KR20240025611A (enExample) |
| CN (1) | CN117545467A (enExample) |
| AU (1) | AU2022296780A1 (enExample) |
| CA (1) | CA3222851A1 (enExample) |
| IL (1) | IL309578A (enExample) |
| MX (1) | MX2023014901A (enExample) |
| WO (1) | WO2022268913A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| KR20250029793A (ko) | 2022-05-24 | 2025-03-05 | 바이오-트립 비.브이. | 지질 나노입자를 위한 표적화 바디를 갖는 변형된 아포리포단백질 |
| EP4688163A1 (en) | 2023-03-29 | 2026-02-11 | Bio-TRIP B.V. | Apolipoprotein lipid nanoparticle |
| WO2025190968A1 (en) | 2024-03-11 | 2025-09-18 | Bio-Trip B.V. | Apolipoprotein lipid nanoparticle |
| WO2026029597A1 (ko) * | 2024-07-31 | 2026-02-05 | 주식회사 메디치바이오 | 신규한 스테롤 지질 또는 이의 유도체를 함유하는 지질 나노입자 조성물 |
| GB202412885D0 (en) * | 2024-09-03 | 2024-10-16 | Imperial College Innovations Ltd | Three component lipid nanoparticles |
| CN120607455B (zh) * | 2025-08-06 | 2025-10-21 | 中国科学院长春应用化学研究所 | 可电离脂质、其立体异构体或药学上可接受的盐、制备方法和应用 |
| CN121059567A (zh) * | 2025-11-07 | 2025-12-05 | 中国医学科学院输血研究所 | 一种脂质纳米颗粒及其应用、药物递送载体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4995423B2 (ja) * | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| EP2217221B1 (en) * | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| US8268796B2 (en) * | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
| EP3243504A1 (en) * | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| EP3713548A4 (en) | 2017-11-21 | 2021-06-23 | Icahn School of Medicine at Mount Sinai | Promoting trained immunity with therapeutic nanobiologic compositions |
| GB201800370D0 (en) * | 2018-01-10 | 2018-02-21 | Ucl Business Plc | Anionic nanocomplexes for nucleic acid delivery |
| EP3947646A1 (en) * | 2019-04-05 | 2022-02-09 | Precision BioSciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| WO2020219833A1 (en) * | 2019-04-26 | 2020-10-29 | Northwestern University | High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy |
-
2022
- 2022-06-22 CA CA3222851A patent/CA3222851A1/en active Pending
- 2022-06-22 IL IL309578A patent/IL309578A/en unknown
- 2022-06-22 KR KR1020247001941A patent/KR20240025611A/ko active Pending
- 2022-06-22 WO PCT/EP2022/067073 patent/WO2022268913A1/en not_active Ceased
- 2022-06-22 JP JP2023579371A patent/JP2024526202A/ja active Pending
- 2022-06-22 AU AU2022296780A patent/AU2022296780A1/en active Pending
- 2022-06-22 MX MX2023014901A patent/MX2023014901A/es unknown
- 2022-06-22 US US18/572,415 patent/US20240216291A1/en active Pending
- 2022-06-22 CN CN202280044949.4A patent/CN117545467A/zh active Pending
- 2022-06-22 EP EP22735885.0A patent/EP4358936A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4358936A1 (en) | 2024-05-01 |
| JP2024526202A (ja) | 2024-07-17 |
| US20240216291A1 (en) | 2024-07-04 |
| IL309578A (en) | 2024-02-01 |
| KR20240025611A (ko) | 2024-02-27 |
| AU2022296780A9 (en) | 2023-12-14 |
| CA3222851A1 (en) | 2022-12-29 |
| WO2022268913A1 (en) | 2022-12-29 |
| CN117545467A (zh) | 2024-02-09 |
| AU2022296780A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014901A (es) | Nanoparticulas que contienen acido nucleico. | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| ZA202101465B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| EP4635481A3 (en) | Biodegradable lipids for the delivery of active agents | |
| ZA202300131B (en) | Lipid nanoparticles | |
| MX2022007680A (es) | Nanoparticulas lipidicas para administracion de acidos nucleicos. | |
| MX2024000327A (es) | Composiciones y metodos para la administracion de arn mensajero. | |
| WO2020051220A8 (en) | Compositions and methods for organ specific delivery of nucleic acids | |
| EP3964200A1 (en) | Compositions and methods for delivery of therapeutic agents | |
| JOP20200050A1 (ar) | عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام | |
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| MX2019011004A (es) | Compuestos y composiciones para la administracion intracelular de agentes terapeuticos. | |
| MX2012014079A (es) | Lipidos biodegradables para la administracion de agentes activos. | |
| EP4036079A3 (en) | Compounds and compositions for intracellular delivery of agents | |
| HK1250009A1 (zh) | 用於将rna和水溶性治疗有效化合物递送到靶细胞的脂质颗粒制剂 | |
| BR112014018432A8 (pt) | Proteína, composição imunogênica, método para produzir proteína e para tratar ou prevenir doença, molécula de ácido nucleico, vetor, célula hospedeira, uso de uma proteína, e, uso de uma composição imunogênica | |
| EP4286012A3 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| MX2017015037A (es) | Composiciones nutritivas que contienen un nivel elevado de inositol y usos de las mismas. | |
| IN2015DN03219A (enExample) | ||
| EP2574170A4 (en) | IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS | |
| ZA202403337B (en) | Lipid nanoparticles for oligonucleotide delivery | |
| BRPI0417932A (pt) | lipólise medicamentosa de acúmulo de gordura | |
| MX341918B (es) | Formulación de liposomas adecuada para tratar o prevenir la tuberculosis. | |
| MX2025010536A (es) | Nuevas formulaciones de nanoparticulas lipidicas para la administracion de acidos nucleicos |